{rfName}
Di

Indexed in

License and use

Altmetrics

Grant support

This work was supported by Asociacion Espanola Contra el Cancer (AECC CICPFI6025SALA), Fondo de Investigaciones Sanitarias Instituto de Salud Carlos III (Miguel Servet Program CP13/00159 and PI15/00580 to I.S.), Spanish Ministerio de Economia y Competitividad (SAF201564885-R to E.C.), Generalitat de Catalunya Suport Grups de Recerca (2017-SGR-1107 to I.S. and 2017-SGR-1142 to E.C.), SPECS II grant (National Cancer Institute 1U01CA157581), and the European Regional Development Fund (Una manera de fer Europa). J.E.R.-Z. was supported by a fellowship from Generalitat de Catalunya AGAUR FI-DGR 2017 (2017 FI_B01004). E.C. is an Academia Researcher of the Institucio ' Catalana de Recerca i Estudis Avancats of the Generalitat de Catalunya. This work was developed at the Centro Esther Koplowitz, Barcelona, Spain. The group is supported by Accioinstrumental d'incorporacio de cientifics i tecnolegs PERIS 2016 (SLT002/16/00336 to Noelia Garcia) from Generalitat de Catalunya.

Analysis of institutional authors

Ramis-Zaldivar JeAuthorRamis Zaldivar, Joan EnricAuthorGonzalez-Farre BAuthorBalagué Ponz, OlgaAuthorNadeu FAuthorSalmeron-Villalobos JAuthorDlouhy IAuthorClot GAuthorEnjuanes AAuthorLópez-Guillermo AAuthorCampo EAuthorSalaverria ICorresponding Author
Share
Publications
>
Article

Distinct molecular profile of IRF4-rearranged large B-cell lymphoma

Publicated to:Blood. 135 (4): 274-286 - 2020-01-23 135(4), DOI: 10.1182/blood.2019002699

Authors: Enric Ramis-Zaldivar, Joan; Gonzalez-Farre, Blanca; Balague, Olga; Celis, Veronica; Nadeu, Ferran; Salmeron-Villalobos, Julia; Andres, Mara; Martin-Guerrero, Idoia; Garrido-Pontnou, Marta; Gaafar, Ayman; Sunol, Mariona; Barcena, Carmen; Garcia-Bragado, Federico; Andion, Maitane; Azorin, Daniel; Astigarraga, Itziar; Sagaseta de Ilurdoz, Maria; Sabado, Constantino; Gallego, Soledad; Verdu-Amoros, Jaime; Fernandez-Delgado, Rafael; Perez, Vanesa; Tapia, Gustavo; Mozos, Anna; Torrent, Montserrat; Solano-Paez, Palma; Rivas-Delgado, Alfredo; Dlouhy, Ivan; Clot, Guillem; Enjuanes, Anna; Lopez-Guillermo, Armando; Galera, Pallavi; Oberley, Matthew J; Maguire, Alanna; Ramsower, Colleen; Rimsza, Lisa M; Quintanilla-Martinez, Leticia; Jaffe, Elaine S; Campo, Elias; Salaverria, Itziar

Affiliations

Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA - Author
Complejo Hosp Navarra, Pathol Dept, Pamplona, Spain - Author
Complejo Hosp Navarra, Pediat Oncol Dept, Pamplona, Spain - Author
Ctr Invest Biomed Red Canc, Madrid, Spain - Author
Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Inst Pathol, Tubingen, Germany - Author
Hosp Clin Univ Valencia, Pediat Oncol Dept, Valencia, Spain - Author
Hosp St Joan de Deu, Pathol Dept, Esplugas de Llobregat, Spain - Author
Hosp St Joan de Deu, Pediat Oncol Dept, Esplugas de Llobregat, Spain - Author
Hosp St Pau & Santa Creu, Pathol Dept, Barcelona, Spain - Author
Hosp St Pau & Santa Creu, Pediat Oncol Dept, Barcelona, Spain - Author
Hosp Trias & Pujol, Pathol Dept, Badalona, Spain - Author
Hosp Univ & Politecn La Fe Valencia, Pediat Oncol Dept, Valencia, Spain - Author
Hosp Univ 12 Octubre, Pathol Dept, Madrid, Spain - Author
Hosp Univ 12 Octubre, Pediat Oncol Dept, Madrid, Spain - Author
Hosp Univ Cruces Osakidetza, Biocruces Bizkaia Hlth Res Inst, Pathol Dept, Baracaldo, Spain - Author
Hosp Univ Cruces Osakidetza, Biocruces Bizkaia Hlth Res Inst, Pediat Oncol Unit, Baracaldo, Spain - Author
Hosp Univ Infant Nino Jesus, Pathol Dept, Madrid, Spain - Author
Hosp Univ Infant Nino Jesus, Pediat Oncol Dept, Madrid, Spain - Author
Hosp Univ Vall dHebron, Pathol Dept, Barcelona, Spain - Author
Hosp Univ Vall dHebron, Pediat Oncol Dept, Barcelona, Spain - Author
Hosp Virgen Rocio, Pediat Oncol Dept, Seville, Spain - Author
Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain - Author
Mayo Clin, Dept Lab Med & Pathol, Phoenix, AZ USA - Author
Mayo Clin, Dept Res, Scottsdale, AZ USA - Author
NIH, Lab Pathol, Bldg 10, Bethesda, MD 20892 USA - Author
Univ Barcelona, Hosp Clin Barcelona, Hematopathol Unit, Barcelona, Spain - Author
Univ Basque Country, Univ Pais Vasco, Fac Sci & Technol, Dept Genet Phys Anthropol & Anim Physiol, Leioa, Spain - Author
See more

Abstract

Pediatric large B-cell lymphomas (LBCL) share morphological and phenotypic features with adult types but have better prognosis. The higher frequency of some subtypes such as LBCL with IRF4 rearrangement (LBCL-IRF4) in children, suggests that some age-related biological differences may exist. To characterize the genetic and molecular heterogeneity of these tumors, we studied 31 diffuse large B-cell lymphomas, not otherwise specified (DLBCL, NOS), 20 LBCL-IRF4, and 12 high grade B-cell lymphomas, NOS (HGBCL, NOS) in patients {less than or equal to}25 years-old using an integrated approach including targeted gene sequencing, copy number arrays and gene expression profiling. Each subgroup displayed different molecular profiles. LBCL-IRF4 had frequent mutations in IRF4 and NF-kB pathway genes (CARD11, CD79B and MYD88), losses of 17p13 and gains of chr7, 11q12.3-q25 whereas DLBCL,NOS were predominantly of germinal center B-cell (GCB) subtype and carried gene mutations similar to the adult counterpart (e.g. SOCS1 and KMT2D), gains of 2p16/REL and losses of 19p13/CD70. A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma related genes such as MYC, ID3 and DDX3X and homozygous deletions of 9p21/CDKN2A whereas other cases were genetically closer to GCB-DLBCL. Factors related to unfavorable outcome were age >18y old, activated B-cell DLBCL profile, HGBCL, NOS, high genetic complexity, 1q21-q44 gains, 2p16/REL gains/amplifications, 19p13/CD70 homozygous deletions, and TP53 and MYC mutations. In conclusion, these findings further unravel the molecular heterogeneity of pediatric/young-adult LBCL, improve the classification of this group of tumors and provide new parameters for risk stratification.Copyright © 2019 American Society of Hematology.

Keywords
childrenclassificationfollicular lymphomafrequentgene-expressiongenomehigh-resolutionmutationspathogenesisAdolescentAdultBurkitt-lymphomaChildChild, preschoolFemaleHumansInterferon regulatory factor-4Interferon regulatory factorsLymphoma, large b-cell, diffuseMaleMutationPrognosisTranscriptomeYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Blood due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position 1/76, thus managing to position itself as a Q1 (Primer Cuartil), in the category Hematology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.1. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 4.05 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 27.09 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-13, the following number of citations:

  • WoS: 94
  • Scopus: 98
  • Europe PMC: 40
  • OpenCitations: 92
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-13:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 84.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 89 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.75.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 6 (Altmetric).
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Germany; United States of America.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Ramis Zaldivar, Joan Enric) and Last Author (Salaverria Frigola, Itziar).

the author responsible for correspondence tasks has been Salaverria Frigola, Itziar.